[Express Train - Episode 63] Seegene Demonstrates Technological Excellence with Molecular Diagnostics

Seegene is an in vitro diagnostics company that diagnoses diseases from patient-collected specimens such as saliva, urine, cerebrospinal fluid, and blood. Its core business is molecular diagnostics, which differentiates disease causes through genetic (DNA·RNA) analysis.

Molecular diagnostics is the only in vitro diagnostic method that enables early diagnosis and allows preventive medicine and personalized treatment, making it the fastest-growing sector in the in vitro diagnostics market. The value of companies possessing molecular diagnostic technology is increasingly gaining attention compared to those with only in vitro diagnostic technology. Seegene developed a diagnostic kit for the novel coronavirus infection (COVID-19).

Patent attorney Eom Jeong-han from BLT Patent Law Firm reviewed Seegene’s patent and trademark application status.

Listed companies on the domestic stock market disclose patent acquisition facts through the Financial Supervisory Service’s electronic disclosure system. However, many stock investors tend to overlook patent disclosures.

Not only patents but also trademark registrations signal the future direction of listed companies, making them one of the important indicators for assessing future corporate value. Some patent disclosures even act as a direct trigger for stock price increases.

It is not easy for ordinary investors to understand the impact on companies through patent disclosures or to check trademark application statuses one by one. Asia Economy, together with patent attorney Eom Jeong-han from BLT Patent Law Firm, is reviewing the patent and trademark application statuses of listed companies through the 'Express Train.'

The Express Train is an abbreviation for a broadcast that diligently searches for rapidly rising stocks through patents.

This content was produced with the assistance of AI translation services.